method
retrospect
cohort
studi
involv
consecut
patient
specimen
posit
revers
transcriptasepolymeras
chain
reaction
matrix
new
gene
conduct
result
nontreat
oseltamivirtr
patient
compar
viral
load
present
demographi
present
symptom
correl
observ
viral
load
age
number
symptom
viral
load
nasopharyng
aspir
npa
signifi
cantli
lower
treat
nontreat
patient
day
symptom
onset
oseltamivir
initi
day
symptom
onset
greater
rate
viral
load
reduct
npa
treat
patient
nontreat
patient
observ
ci
vs
ci
log
copiesmld
postsymptom
onset
viral
load
undetect
day
oseltamivir
initi
day
earlier
whose
treatment
initi
day
symptom
onset
viral
load
invers
correl
concomit
absolut
lymphocyt
count
nontreat
patient
pearson
correl
coeffi
cient
r
p
treat
patient
pearson
r
p
resolut
fever
day
later
nontreat
treat
patient
p
conclus
natur
viral
load
profi
le
describ
oral
oseltamivir
suppress
viral
load
effect
given
earli
mild
case
pandem
infl
uenza
infect
abbrevi
histidin
mutat
hb
hemoglobin
lym
absolut
lymphocyt
npa
nasopharyng
aspir
np
nasopharyng
swab
nt
nasothroat
swab
pandem
pandem
infl
uenza
plt
platelet
rtpcr
revers
transcriptasepolymeras
chain
reaction
download
respiratori
specimen
patient
taken
nasopharyng
aspir
npa
nasopharyng
swab
np
nasothroat
manuscript
dissemin
global
mexico
unit
state
sinc
april
sustain
humantohuman
transmiss
contin
world
health
organ
rais
pandem
alert
level
phase
phase
june
global
popul
age
year
undetect
neutral
antibodi
diseas
expect
spread
throughout
next
year
sever
second
wave
winter
initi
anim
studi
suggest
pandem
also
replic
lower
respiratori
tract
elicit
infl
ammatori
damag
season
infl
uenza
virus
although
casefat
rate
outsid
mexico
compar
season
infl
uenza
much
higher
mexico
occur
age
year
effect
pandem
vaccin
avail
fi
rst
month
pandem
oral
oseltamivir
recommend
chemoprophylaxi
treatment
contain
mitig
measur
although
case
oseltamivirresist
isol
relat
neuraminidas
histidin
mutat
report
viral
isol
still
suscept
oseltamivir
vitro
test
oseltamivir
treatment
shown
safe
reduc
diseas
durat
day
incid
secondari
swab
nt
sent
viral
transport
medium
present
day
hospit
total
nucleic
acid
extract
use
nuclisen
easymag
instrument
biomerieux
durham
nc
rtpcr
infl
uenza
viru
matrix
pandem
season
gene
perform
previous
describ
posit
control
swine
viru
human
season
virus
includ
quantit
assay
rtpcr
target
matrix
gene
perform
forward
primer
cttctaaccgaggtcgaaacg
revers
primer
ggcattttggacaaakcgtcta
cdna
amplifi
ed
lightcycl
instrument
faststart
dna
master
sybr
green
mix
reagent
kit
refer
standard
prepar
use
pcriitopo
vector
invitrogen
san
diego
ca
nontreat
pandem
infect
patient
treat
oseltamivir
compar
regard
demograph
underli
comorbid
initi
present
symptom
laboratori
paramet
viral
load
npa
differ
day
post
symptom
onset
viral
load
npa
nontreat
oseltamivir
initi
day
post
symptom
onset
compar
viral
load
nontreat
treat
patient
interv
post
symptom
onset
compar
x
test
fisher
exact
test
use
categor
variabl
independ
test
continu
variabl
two
group
oneway
analysi
varianc
use
compar
viral
load
npa
np
nt
interv
post
symptom
onset
within
nontreat
treat
patient
linear
regress
use
determin
rate
viral
load
reduct
pearson
correl
use
test
correl
age
number
present
symptom
concomit
total
wbc
count
absolut
lymphocyt
lym
count
hemoglobin
hb
level
platelet
plt
count
viral
load
respect
spss
window
spss
inc
chicago
il
use
statist
comput
twotail
p
valu
consid
signifi
cant
one
hundr
fortyf
patient
diagnos
pandem
infect
period
sinc
begin
epidem
hong
kong
includ
sixtyon
male
patient
seventysix
patient
age
year
none
age
year
twentyseven
patient
refus
treatment
enrol
case
patient
receiv
oseltamivir
control
refus
relat
fear
possibl
side
effect
oseltamivir
despit
counsel
attend
clinician
none
diabet
mellitu
chronic
obstruct
airway
diseas
two
patient
mild
pneumon
chang
right
middl
lower
lobe
chest
radiograph
respect
none
evid
rhabdomyolysi
myocard
enceph
nontreat
treat
patient
compar
demograph
comorbid
present
symptom
initi
laboratori
paramet
tabl
oseltamivir
initi
day
day
day
day
complic
pneumonia
otiti
media
initi
within
h
symptom
onset
season
infl
uenza
easili
administ
oral
safe
drug
patient
asthma
evid
effect
treatment
pandem
remain
uncertain
current
recommend
base
assumpt
pandem
similar
biolog
characterist
season
infl
uenza
virus
compar
viral
load
profi
le
fi
rst
group
pandem
infect
patient
without
oseltamivir
treatment
hong
kong
contain
phase
pandem
outbreak
hong
kong
april
june
patient
laboratoryconfi
rmed
pandem
infect
local
prevent
control
diseas
ordin
compulsorili
isol
isol
three
hospit
hong
kong
includ
studi
studi
approv
institut
review
board
addit
draw
blood
routin
hematolog
biochem
test
chest
radiograph
taken
clinic
indic
nasopharyng
specimen
test
posit
revers
transcriptasepolymeras
chain
reaction
rtpcr
infl
uenza
matrix
gene
pandem
hemagglutinin
gene
neg
season
day
oseltamivir
recommend
dosag
adjust
age
renal
function
refus
oseltamivir
treatment
regard
case
studi
natur
viral
load
profi
le
upper
respiratori
specimen
wherea
treat
control
demograph
clinic
laboratori
radiograph
data
retrospect
retriev
computer
clinic
manag
system
entri
standard
form
analysi
previous
describ
number
classic
initi
clinic
symptom
predictor
infl
uenza
infect
use
correl
viral
load
respiratori
specimen
includ
presenc
fever
temperatur
cough
sore
throat
nasal
symptom
myalgia
headach
day
post
symptom
onset
mean
rang
interv
symptom
onset
oseltamivir
initi
day
six
patient
nonspecifi
c
complaint
nausea
vomit
loos
stool
initi
day
oseltamivir
therapi
diffi
cult
differenti
clinic
symptom
pandem
infect
none
report
major
side
effect
oseltamivir
therapi
viral
load
npa
np
nt
differ
interv
post
symptom
onset
nontreat
patient
compar
fig
tabl
wherea
signific
differ
observ
day
day
post
symptom
onset
treat
patient
fig
b
tabl
treat
patient
viral
load
npa
higher
np
nt
signifi
cant
differ
observ
day
post
oseltamivir
initi
day
day
oseltamivir
initi
fig
tabl
similar
fi
nding
observ
day
post
oseltamivir
initi
receiv
oseltamivir
day
post
symptom
onset
day
post
oseltamivir
initi
receiv
oseltamivir
day
post
symptom
onset
npa
specimen
analyz
viral
load
npa
signifi
cantli
lower
treat
nontreat
patient
day
post
symptom
onset
irrespect
relat
oseltamivir
initi
day
post
symptom
onset
fig
tabl
oseltamivir
initi
day
post
symptom
onset
greater
rate
viral
load
reduct
npa
treat
patient
ci
vs
ci
log
copiesmld
post
symptom
onset
nontreat
patient
observ
similar
rate
viral
load
reduct
npa
observ
receiv
oseltamivir
day
symptom
onset
ci
vs
ci
log
copiesmld
post
oseltamivir
initi
day
post
oseltamivir
initi
patient
undetect
viral
load
level
respiratori
specimen
fig
b
viral
load
level
npa
undetect
day
earlier
receiv
oseltamivir
day
post
symptom
onset
moreov
viral
load
npa
receiv
oseltamivir
day
post
symptom
onset
consist
lower
nontreat
patient
signifi
cant
differ
observ
day
day
post
symptom
onset
fig
tabl
among
viral
load
test
perform
sampl
nontreat
patient
sampl
treat
control
concomit
peripher
blood
taken
hematolog
test
viral
load
level
invers
correl
concomit
lym
count
pearson
r
p
hb
level
pearson
r
p
plt
count
pearson
r
p
treat
patient
antivir
therapi
infl
uenza
hamper
earli
peak
viral
load
leav
narrow
window
opportun
antivir
treatment
season
pandem
infl
uenza
infect
viral
load
peak
around
day
post
symptom
onset
natur
infect
healthi
adult
without
oseltamivir
treatment
data
yet
report
treatment
effect
oseltamivir
pandem
infect
reassur
observ
treat
patient
similar
fi
nding
obtain
lym
count
pearson
r
p
wbc
count
pearson
r
p
hb
level
plt
count
nontreat
patient
signifi
cant
correl
observ
viral
load
level
patient
age
number
classic
present
symptom
resolut
fever
temperatur
day
earlier
treat
nontreat
patient
vs
day
p
none
requir
ventilatori
critic
care
death
report
recent
year
oseltamivir
resist
larg
associ
mutat
neuraminidas
gene
influenza
virus
develop
patient
follow
oseltamivir
treatment
mutant
infl
uenza
brisbanelik
variant
fi
rst
detect
norway
spread
global
becom
domin
season
viru
initi
bioinformat
analysi
phenotyp
antivir
suscept
test
show
suscept
oseltamivir
zanamivir
resist
amantadin
rimantadin
serin
mutat
dramat
increas
oseltamivir
use
treat
pandem
infect
resist
may
continu
increas
worldwid
includ
hong
kong
even
avail
safe
effect
pandem
vaccin
antivir
stockpil
remain
import
armamentarium
epidemiolog
control
futur
pandem
earli
control
viral
load
patient
treat
oseltamivir
may
explain
action
innat
immun
follow
earli
anamnest
adapt
immun
respons
possibl
cytotox
lymphocyt
respons
crossreact
epitop
intern
protein
nonneutr
surfac
protein
common
infl
uenza
virus
failur
mount
earli
immun
respons
innat
humor
cellular
immunodefi
cienci
concomit
use
immunosuppress
drug
transient
immunoparesi
due
sever
concomit
coinfect
may
predispos
patient
develop
sever
clinic
progress
often
present
late
hospit
median
day
respiratori
failur
death
median
day
post
symptom
onset
viral
load
refl
ect
dynam
interact
viral
replic
clearanc
bodi
defens
mechan
monitor
viral
load
throughout
diseas
cours
use
object
mean
check
clinic
progress
respons
antivir
therapi
show
invers
correl
absolut
lymphocyt
count
concomit
viral
load
level
greater
rate
viral
suppress
respiratori
specimen
throughout
diseas
cours
significantli
lower
viral
load
day
post
symptom
onset
moreov
oseltamivir
initi
day
symptom
onset
viral
load
detect
day
post
oseltamivir
day
treatment
complet
day
earlier
initi
day
symptom
onset
effect
oseltamivir
earli
treatment
suppress
pandem
similar
season
infl
uenza
although
effect
pandem
chemoprophylaxi
yet
establish
fever
subsid
day
earlier
treat
patient
consist
previou
fi
nding
oseltamivir
shorten
fever
durat
reduc
quantiti
durat
viral
shed
adult
season
infl
uenza
although
oseltamivir
shown
hasten
recoveri
reduc
viral
load
studi
longterm
effect
pandem
remain
uncertain
primari
resist
neuraminidas
inhibitor
among
wild
strain
human
infl
uenza
virus
b
uncommon
tabl
valu
given
mean
sd
viral
load
log
copiesml
specimen
detect
limit
quantit
rtpcr
log
copiesml
see
tabl
expans
abbrevi
valu
given
mean
sd
viral
load
log
copiesml
specimen
detect
limit
quantit
rtpcr
log
copiesml
fnp
fl
ock
nasopharyng
swab
npa
nasopharyng
aspir
np
nasopharyng
swab
nt
nasothroat
swab
snp
standard
nasopharyng
swab
rtpcr
revers
transcriptasepolymeras
chain
reaction
aspir
like
get
good
sampl
infect
cell
swab
throat
anterior
nare
even
nasopharynx
viral
load
decreas
oseltamivir
differ
would
accentu
suboptim
sampl
method
np
nt
factor
unlik
affect
overal
conclus
studi
result
similar
nasopharyng
aspir
analyz
similar
previou
studi
oseltamivir
associ
side
effect
frequent
side
effect
gastrointestin
symptom
occur
school
children
receiv
oseltamivir
prophylaxi
infl
uenza
viru
previou
report
suggest
seriou
neuropsychiatr
manifest
oseltamivir
demonstr
later
studi
school
children
take
oseltamivir
prophylaxi
report
mild
symptom
nontreat
treat
patient
irrespect
day
post
symptom
onset
time
specimen
sampl
case
sar
coronaviru
infl
uenza
viru
infect
lymphopenia
note
pandem
infect
patient
greater
sever
especi
pregnant
morbidli
obes
previou
studi
immunocompromis
patient
show
lymphocyt
recoveri
associ
viral
clearanc
independ
oseltamivir
differ
viral
load
differ
sampl
method
nontreat
patient
wherea
differ
seen
npa
np
nt
treat
patient
could
attribut
increas
statist
power
higher
number
patient
specimen
group
domin
site
viral
replic
mild
case
nasopharynx
rather
lower
respiratori
tract
suction
nasopharyng
valu
given
mean
sd
viral
load
log
copiesml
specimen
detect
limit
quantit
rtpcr
log
copiesml
see
tabl
valu
given
mean
sd
viral
load
log
copiesml
specimen
detect
limit
quantit
rtpcr
log
copiesml
see
tabl
expans
abbrevi
despit
appar
effi
caci
oseltamivir
mild
case
effi
caci
stop
diseas
progress
late
case
remain
uncertain
random
control
treatment
trial
possibl
begin
epidem
local
uncertainti
diseas
sever
intern
recommend
oseltamivir
treatment
moreov
patient
present
us
differ
day
post
symptom
onset
refus
nasopharyng
sampl
symptom
improv
despit
limit
nontreat
case
still
compar
treat
patient
demograph
symptom
laboratori
fi
nding
previou
viral
load
studi
pandem
infect
focus
oseltamivirtr
patient
fi
rst
studi
knowledg
natur
viral
load
profi
le
patient
without
treatment
